LASSBio-1632

• UNSPSC Description:

  LASSBio-1632 is a new anti-asthmatic lead candidate associated with selective inhibition of PDE4A and PDE4D isoenzymes and blockade of airway hyper-reactivity (AHR) and TNF-α production in the lung tissue. LASSBio-1632 (7j) displays high experimental BBB permeability across BBB through passive diffusion[1].

• Target Antigen:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/lassbio-1632.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=CC2=C(C=C1S(N(/N=C/C3=CC=C(C(OC)=C3)OC)C)(=O)=O)OCO2

• Molecular Weight:

  392.43

• References & Citations:

  [1]Isabelle Karine da Costa Nunes, et al. Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies. Eur J Med Chem. 2020 Jul 18;204:112492.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3029936-02-2